Autonomix Medical shares surge 10.12% intraday after presenting new sub-group data showing rapid pain relief in pancreatic cancer patients at 2026 ASCO GI meeting.

Autonomix Medical surged 10.12% intraday, as the company presented new sub-group data at the 2026 ASCO GI meeting, showing rapid, durable pain relief in pancreatic cancer patients (Stages 2-4), with 93.75% (N=16) improving from severe to mild/moderate pain within 7 days. The company focuses on precision nerve-targeted therapies, utilizing its radiofrequency denervation platform for severe cancer-related pain management.